Fact sheet
Anti Cell Proliferative
- -
- Pipeline
- Pericyte Protective Agent
- Long-acting CGRP
- Long-acting Pramlintide
- Anti Cell Proliferative
ASX 
LCT 0.017 Last updated EOD 18th December 2019
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Alternatively you might like to contact us.
Anti Cell Proliferative
NO FURTHER INVESTMENT IN THIS TARGET
Target: Glioma
Gliomas are the most common primary brain tumour, making up 81 percent of malignant brain tumours. Although relatively rare, they are highly malignant. Glioblastoma, the most common glioma, has a 5-year relative survival of less than 5 percent. There is currently no cure.
Working with Sir Richard Faull’s Centre for Brain Research, we evaluated compounds that prevent human glioma cells from proliferating in vitro.
At this point, our due diligence identified that this is a difficult target. Consequently, we decided not to invest further in this project.
